Procarbazine – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 58 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Procarbazine - Uses, Dosage, Side Effects, Interactions
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. Procarbazine therapy has been associated with serum enzyme elevations during therapy and with rare cases of idiosyncratic, clinically apparent acute liver injury....

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. Procarbazine therapy has been associated with serum enzyme elevations during therapy and with rare cases of idiosyncratic, clinically apparent acute liver injury. Procarbazine is a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindication in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. Procarbazine therapy has been associated with serum enzyme elevations during therapy and with rare cases of idiosyncratic, clinically apparent acute liver injury.

Procarbazine is a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals that damage DNA through an alkylation reaction.

Procarbazine is a benzamide obtained by formal condensation of the carboxy group of 4-[(2-dimethylhydrazine)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for the treatment of Hodgkin’s lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands. It has a role as an antineoplastic agent. It is a member of hydrazines and a member of benzamides. It is a conjugate base of procarbazine(1+).

Procarbazine Hydrochloride is the hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals that damage DNA through an alkylation reaction.

Mechanism of Action

The precise mode of cytotoxic action of procarbazine has not been clearly defined. There is evidence that the drug may act by inhibition of protein, RNA and DNA synthesis. Studies have suggested that procarbazine may inhibit the transmethylation of methyl groups of methionine into t-RNA. The absence of functional t-RNA could cause the cessation of protein synthesis and consequently DNA and RNA synthesis. In addition, procarbazine may directly damage DNA. Hydrogen peroxide, formed during the auto-oxidation of the drug, may attack protein sulfhydryl groups contained in residual protein which is tightly bound to DNA. Procarbazine is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands – directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Procarbazine is cell-phase specific for the S phase of cell division.

or

O-6-Methylguanine was measured in the blood infection. সহজ বাংলা: শ্বেত রক্তকণিকা।" data-rx-term="leukocyte" data-rx-definition="Leukocyte means white blood cell, which helps fight infection. সহজ বাংলা: শ্বেত রক্তকণিকা।">leukocyte DNA of seven patients with Hodgkin’s or non-Hodgkin’s lymphoma during therapeutic exposure to procarbazine involving three daily p.o. doses (50 mg each) for 10 days (corresponding to 2.1 mg/kg/day for a 70-kg human). Adduct accumulation was observed in all seven cases, reaching levels up to 0.28 fmol/microgram of DNA (0.45 umol/mol of guanine). In one individual, maximal levels of adduct were reached after 7 days of exposure, followed by a steady decline, whereas in all other individuals continuous accumulation was observed throughout the exposure period. In four individuals for which data were available for day 11 (12 to 16 hr after the final intake of procarbazine), decreased amounts of O-6-methylguanine were observed relative to the last previous measurements. The accumulation of O-6-methylguanine was linearly correlated with the cumulative dose of procarbazine, with a slope of 0.011 fmol of O-6-methylguanine/microgram of DNA per mg/kg of body weight or 2.68×10-4 fmol of O-6-methylguanine DNA per mg/sq m. Two hr after the administration of single p.o. doses of l to 10 mg/kg of procarbazine to rats, O-6-methylguanine formation in infection. সহজ বাংলা: শ্বেত রক্তকণিকা।" data-rx-term="leukocyte" data-rx-definition="Leukocyte means white blood cell, which helps fight infection. সহজ বাংলা: শ্বেত রক্তকণিকা।">leukocyte DNA was just under half that in liver DNA and showed a linear relationship with dose with a slope of 0.017 fmol/microgram of DNA per mg/kg of body weight or 5.67×10-4 fmol of O-6-methylguanine/microgram of DNA per mg/sq m. A negative correlation between the rate of accumulation of O-6-methylguanine in different individuals and lymphocyte O-6-alkylguanine-DNA alkyltransferase was observed, demonstrating a probable protective effect of O-6-alkylguanine-DNA alkyltransferase against the accumulation of O-6-methylguanine during exposure to methylating agents. This observation supports the suggestion of a possible role of procarbazine-induced O-6-methylguanine in the pathogenesis of acute nonlymphocytic leukemia appearing after treatment with chemotherapeutic protocols which include procarbazine, based on the finding of low lymphocyte O-6-alkylguanine-DNA alkyltransferase levels in patients with such therapy-related neoplastic disease. Lymphocyte O-6-alkylguanine-DNA alkyltransferase levels were mainly in the range of 5 to 10 fmol/micrograms of DNA and showed no consistent variation during procarbazine exposure.

Indications

  • For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin’s disease.
  • Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. Procarbazine therapy has been associated with serum enzyme elevations during therapy and with rare cases of idiosyncratic, clinically apparent acute liver injury.
  • Non-Hodgkin’s Lymphoma (NHL)
  • Oligodendrogliomas
  • Primary Central Nervous System Lymphoma (PCNSL)
  • Stage III Hodgkin’s Disease
  • Stage IV Hodgkin’s Disease
  • Non-Hodgkin’s Lymphoma (NHL)
  • Oligodendrogliomas
  • Primary Central Nervous System Lymphoma (PCNSL)
  • Stage III Hodgkin’s Disease
  • Stage IV Hodgkin’s Disease

Contraindication

The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:

  • is allergic to procarbazine or to any of the ingredients of the medication
  • has severe depletion of neutrophils (white blood cells), platelets, or red blood cell
  • a bacterial infection
  • opportunistic fungal infection
  • an infection due to a protozoa organism
  • decreased function of bone marrow
  • anemia
  • increased risk of bleeding due to clotting disorder
  • decreased blood platelets
  • low levels of white blood cells
  • alcoholism
  • a painful condition that affects the nerves in the legs and arms called peripheral pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।" data-rx-term="neuropathy" data-rx-definition="Neuropathy means nerve damage or irritation causing pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।">neuropathy
  • liver problems
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • kidney disease with likely reduction in kidney function
  • an increased risk of developing an uncommon viral infection called an opportunistic infection

Dosage

Strengths: 50 mg

Hodgkin’s Disease

As a single agent:

  • Initial dose: Single or divided doses of 2 to 4 mg/kg/day orally for one week (to minimize nausea and vomiting experienced by a high percentage of patients beginning therapy)
  • Maintenance dose: 4 to 6 mg/kg/day orally until a maximum response is obtained or until the white blood count falls below 4000 or the platelets fall below 100,000; when the maximum response is obtained the dose may be maintained at 1 to 2 mg/kg/day orally
  • Discontinue therapy for hematologic or other toxicity until satisfactory recovery, then resume therapy (at the discretion of the physician based on patient evaluation and laboratory studies) at 1 to 2 mg/kg/day

In combination with other anticancer drugs:

  • The dose of this drug should be reduced (e.g., in the MOPP regimen, the dose is 100 mg/m2/day for 14 days)

Usual Pediatric Dose for Hodgkin’s Disease

Close clinical monitoring is necessary to minimize toxicity (e.g., tremors, coma, convulsions). Dosage should be individualized. The following dosage schedule is provided as a guideline only:

  • Initial dose: 50 mg/m2/day orally for the first week
  • Maintenance dose: 100 mg/m2/day orally until a maximum response is obtained or until leukopenia or platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia occurs; when the maximum response is obtained the dose may be maintained at 50 mg/m2/day orally
  • Discontinue therapy for hematologic or other toxicity until satisfactory recovery, then resume therapy (at the discretion of the physician based on patient evaluation and laboratory studies).

Side Effects

The Most Common

  • nausea, vomiting,
  • leukopenia and platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia
  • somnolence, lethargy, hallucinations, confusion,
  • agitation,
  • cerebellar ataxia,
  • paresthesias, myalgia, a
  • decrease of deep tendon reflexes,
  • hypotension and allergic skin reactions.
  • arthralgia, fever, weakness,
  • dermatitis, coma, alopecia, and convulsions.
  • anorexia, stomatitis, diarrhea, drowsiness, and depression.
  • bone marrow depression,
  • hemolysis, bleeding tendencies, psychoses, dizziness,
  • peripheral neuropathy, tremors, flu-like syndrome,
  • pulmonary reactions, tachycardia,
  • ocular defects such as blurred vision and
  • papilledema, impaired liver function,

More Common

  • shortness of breath, pneumonitis, and productive cough.
  • peripheral leukocyte and platelet counts,
  • optic neuroretinitis and pulmonary eosinophilia.
  • anemia, dry mouth, dysphagia,
  • constipation, fatigue pruritus,
  • herpes, hyperpigmentation, flushing, intercurrent infections,
  • pleura effusion, edema,
  • jaundice, headache,
  • apprehension, nervousness,
  • inability to focus, insomnia,
  • pyrexia, hypersensitivity reactions,
  • hemorrhage, pancytopenia eosinophilia,
  • petechiae, purpura, epistaxis,
  • hemoptysis, hematemesis, melena,
  • nystagmus, urticaria, hearing loss,
  • \diaphoresis, chills, hoarseness,
  • slurred speech, enteritis, nightmares, falling,
  • unsteadiness, abdominal pain, syncope, retinal hemorrhage,
  • photophobia, diplopia, hematuria,
  • urinary frequency, nocturia, foot drop and fetal harm.
  • palpitations, sweating,
  • hypotension and dyspnea.

Rare

  • cough
  • diarrhea
  • fainting
  • fever
  • fast, slow, or pounding heartbeat
  • hallucinations (hearing or seeing things that aren’t there)
  • missing menstrual periods
  • shortness of breath
  • signs of bleeding (e.g., unusual bruising or bleeding, pinpoint red spots on skin, black tarry stools, bloody nose, blood in urine, coughing blood, cuts that don’t stop bleeding)
  • signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide)
  • signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools)
  • lung infection (e.g., difficulty breathing, shortness of breath, wheezing)
  • skin rash, hives, or itching
  • sores in mouth and on lips
  • symptoms of a urinary tract infection (e.g. pain when urinating, urinating more often than usual, low back or flank pain)
  • tingling or numbness of fingers or toes
  • tiredness or weakness (continuing)
  • unusual infections (symptoms may include fever or chills, sore throat, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, painful or difficult urination, or listlessness)
  • vision changes (e.g., blurred vision, increased sensitivity to sunlight)

Drug interactions

Pregnancy and Lactation

FDA Pregnancy Category D

Pregnancy

There is a possibility of birth defects if either the father or mother is taking procarbazine at the time of conception, or if it is taken during pregnancy. This medication should not be used during pregnancy unless the benefits outweigh the risks. Use effective birth control while you are being treated with this medication. If you become pregnant while taking this medication, contact your doctor immediately.

Breast-feeding

It is not known if procarbazine passes into breast milk. If you are a breast-feeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.

How should this medicine be used?

Procarbazine comes as a capsule to take by mouth. It is usually taken one or more times a day. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have. Take procarbazine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take procarbazine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Your doctor may adjust your dose of procarbazine or stop your treatment for a period of time depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment.

What special precautions should I follow?

Before taking procarbazine,

  • tell your doctor and pharmacist if you are allergic to procarbazine, any other medications, or any of the ingredients in procarbazine capsules. Ask your pharmacist for a list of the ingredients.
  • tell your doctor if you are taking or you plan to take any of the following prescription or non-prescription medications: certain antidepressants including amitriptyline (Elavil) and imipramine (Tofranil); medications for asthma; medications for allergies, hay fever; medications containing alcohol (cough and cold products, such as Nyquil, and other liquid products); and nasal decongestants, including nose drops and sprays. Your doctor may tell you not to take these medications with procarbazine and may suggest other treatment(s).
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: barbiturate medications such as phenobarbital; medications for high blood pressure; medications for nausea or mental illness; opioid (narcotic) medications for pain; sedatives; sleeping pills; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with procarbazine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you have received radiation therapy or other chemotherapy within the last 4 weeks.
  • tell your doctor if you have or have ever had kidney or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. You should not become pregnant or breast-feed while you are taking procarbazine. If you become pregnant while receiving procarbazine, call your doctor. Procarbazine may harm the fetus.
  • know that you should not drink alcoholic beverages (including beer and wine) while taking this drug. Alcohol may cause an upset stomach, vomiting, stomach cramps, headaches, sweating, and flushing (redness of the face).
  • tell your doctor if you use tobacco products. Smoking may increase the risk that you will develop other cancers. You should stop smoking.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Procarbazine – Uses, Dosage, Side Effects, Interactions

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action The precise mode of cytotoxic action of procarbazine has not been clearly defined. There is evidence that the drug may act by inhibition of protein, RNA and DNA synthesis. Studies have suggested that procarbazine may inhibit the transmethylation of methyl groups of methionine into t-RNA. The absence of functional t-RNA could cause the cessation of protein synthesis and consequently DNA and RNA synthesis. In addition, procarbazine may directly damage DNA. Hydrogen peroxide, formed during the auto-oxidation of the drug, may attack protein sulfhydryl groups contained in residual protein which is tightly bound to DNA. Procarbazine is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Procarbazine is cell-phase specific for the S phase of cell division. or O-6-Methylguanine was measured in the blood leukocyte DNA of seven patients with Hodgkin's or non-Hodgkin's lymphoma during therapeutic exposure to procarbazine involving three daily p.o. doses (50 mg each) for 10 days (corresponding to 2.1 mg/kg/day for a 70-kg human). Adduct accumulation was observed in all seven cases, reaching levels up to 0.28 fmol/microgram of DNA (0.45 umol/mol of guanine). In one individual, maximal levels of adduct were reached after 7 days of exposure, followed by a steady decline, whereas in all other individuals continuous accumulation was observed throughout the exposure period. In four individuals for which data were available for day 11 (12 to 16 hr after the final intake of procarbazine), decreased amounts of O-6-methylguanine were observed relative to the last previous measurements. The accumulation of O-6-methylguanine was linearly correlated with the cumulative dose of procarbazine, with a slope of 0.011 fmol of O-6-methylguanine/microgram of DNA per mg/kg of body weight or 2.68x10-4 fmol of O-6-methylguanine DNA per mg/sq m. Two hr after the administration of single p.o. doses of l to 10 mg/kg of procarbazine to rats, O-6-methylguanine formation in leukocyte DNA was just under half that in liver DNA and showed a linear relationship with dose with a slope of 0.017 fmol/microgram of DNA per mg/kg of body weight or 5.67x10-4 fmol of O-6-methylguanine/microgram of DNA per mg/sq m. A negative correlation between the rate of accumulation of O-6-methylguanine in different individuals and lymphocyte O-6-alkylguanine-DNA alkyltransferase was observed, demonstrating a probable protective effect of O-6-alkylguanine-DNA alkyltransferase against the accumulation of O-6-methylguanine during exposure to methylating agents. This observation supports the suggestion of a possible role of procarbazine-induced O-6-methylguanine in the pathogenesis of acute nonlymphocytic leukemia appearing after treatment with chemotherapeutic protocols which include procarbazine, based on the finding of low lymphocyte O-6-alkylguanine-DNA alkyltransferase levels in patients with such therapy-related neoplastic disease. Lymphocyte O-6-alkylguanine-DNA alkyltransferase levels were mainly in the range of 5 to 10 fmol/micrograms of DNA and showed no consistent variation during procarbazine exposure. Indications For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease. Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. Procarbazine therapy has been associated with serum enzyme elevations during therapy and with rare cases of idiosyncratic, clinically apparent acute liver injury. Non-Hodgkin's Lymphoma (NHL) Oligodendrogliomas Primary Central Nervous System Lymphoma (PCNSL) Stage III Hodgkin's Disease Stage IV Hodgkin's Disease Non-Hodgkin's Lymphoma (NHL) Oligodendrogliomas Primary Central Nervous System Lymphoma (PCNSL) Stage III Hodgkin's Disease Stage IV Hodgkin's Disease Contraindication The following conditions are contraindicated with this drug. Check with your physician if you have any of the following: is allergic to procarbazine or to any of the ingredients of the medication has severe depletion of neutrophils (white blood cells), platelets, or red blood cell a bacterial infection opportunistic fungal infection an infection due to a protozoa organism decreased function of bone marrow anemia increased risk of bleeding due to clotting disorder decreased blood platelets low levels of white blood cells alcoholism a painful condition that affects the nerves in the legs and arms called peripheral neuropathy liver problems pregnancy a patient who is producing milk and breastfeeding kidney disease with likely reduction in kidney function an increased risk of developing an uncommon viral infection called an opportunistic infection Dosage Strengths: 50 mg Hodgkin's Disease As a single agent: Initial dose: Single or divided doses of 2 to 4 mg/kg/day orally for one week (to minimize nausea and vomiting experienced by a high percentage of patients beginning therapy) Maintenance dose: 4 to 6 mg/kg/day orally until a maximum response is obtained or until the white blood count falls below 4000 or the platelets fall below 100,000; when the maximum response is obtained the dose may be maintained at 1 to 2 mg/kg/day orally Discontinue therapy for hematologic or other toxicity until satisfactory recovery, then resume therapy (at the discretion of the physician based on patient evaluation and laboratory studies) at 1 to 2 mg/kg/day In combination with other anticancer drugs: The dose of this drug should be reduced (e.g., in the MOPP regimen, the dose is 100 mg/m2/day for 14 days) Usual Pediatric Dose for Hodgkin's Disease Close clinical monitoring is necessary to minimize toxicity (e.g., tremors, coma, convulsions). Dosage should be individualized. The following dosage schedule is provided as a guideline only: Initial dose: 50 mg/m2/day orally for the first week Maintenance dose: 100 mg/m2/day orally until a maximum response is obtained or until leukopenia or thrombocytopenia occurs; when the maximum response is obtained the dose may be maintained at 50 mg/m2/day orally Discontinue therapy for hematologic or other toxicity until satisfactory recovery, then resume therapy (at the discretion of the physician based on patient evaluation and laboratory studies). Side Effects The Most Common nausea, vomiting, leukopenia and thrombocytopenia somnolence, lethargy, hallucinations, confusion, agitation, cerebellar ataxia, paresthesias, myalgia, a decrease of deep tendon reflexes, hypotension and allergic skin reactions. arthralgia, fever, weakness, dermatitis, coma, alopecia, and convulsions. anorexia, stomatitis, diarrhea, drowsiness, and depression. bone marrow depression, hemolysis, bleeding tendencies, psychoses, dizziness, peripheral neuropathy, tremors, flu-like syndrome, pulmonary reactions, tachycardia, ocular defects such as blurred vision and papilledema, impaired liver function, More Common shortness of breath, pneumonitis, and productive cough. peripheral leukocyte and platelet counts, optic neuroretinitis and pulmonary eosinophilia. anemia, dry mouth, dysphagia, constipation, fatigue pruritus, herpes, hyperpigmentation, flushing, intercurrent infections, pleura effusion, edema, jaundice, headache, apprehension, nervousness, inability to focus, insomnia, pyrexia, hypersensitivity reactions, hemorrhage, pancytopenia eosinophilia, petechiae, purpura, epistaxis, hemoptysis, hematemesis, melena, nystagmus, urticaria, hearing loss, \diaphoresis, chills, hoarseness, slurred speech, enteritis, nightmares, falling, unsteadiness, abdominal pain, syncope, retinal hemorrhage, photophobia, diplopia, hematuria, urinary frequency, nocturia, foot drop and fetal harm. palpitations, sweating, hypotension and dyspnea. Rare cough diarrhea fainting fever fast, slow, or pounding heartbeat hallucinations (hearing or seeing things that aren't there) missing menstrual periods shortness of breath signs of bleeding (e.g., unusual bruising or bleeding, pinpoint red spots on skin, black tarry stools, bloody nose, blood in urine, coughing blood, cuts that don't stop bleeding) signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide) signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools) lung infection (e.g., difficulty breathing, shortness of breath, wheezing) skin rash, hives, or itching sores in mouth and on lips symptoms of a urinary tract infection (e.g. pain when urinating, urinating more often than usual, low back or flank pain) tingling or numbness of fingers or toes tiredness or weakness (continuing) unusual infections (symptoms may include fever or chills, sore throat, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, painful or difficult urination, or listlessness) vision changes (e.g., blurred vision, increased sensitivity to sunlight) Drug interactions DRUG INTERACTION 1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Procarbazine is combined with 1,2-Benzodiazepine. Abatacept The risk or severity of adverse effects can be increased when Procarbazine is combined with Abatacept. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Abciximab. Acarbose Procarbazine may increase the hypoglycemic activities of Acarbose. Acebutolol Procarbazine may increase the hypotensive activities of Acebutolol. Acenocoumarol The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Acenocoumarol. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Procarbazine. Acetohexamide Procarbazine may increase the hypoglycemic activities of Acetohexamide. Acetophenazine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Acetophenazine. Acetylsalicylic acid The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Acetylsalicylic acid. Acipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Acipimox. Aclidinium Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Procarbazine. Adenovirus type The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Procarbazine. Agomelatine The risk or severity of adverse effects can be increased when Procarbazine is combined with Agomelatine. Albiglutide Procarbazine may increase the hypoglycemic activities of Albiglutide. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Procarbazine. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Procarbazine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Procarbazine. Alendronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procarbazine. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Procarbazine. Alimemazine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Alimemazine. Aliskiren Procarbazine may increase the hypotensive activities of Aliskiren. Allogeneic processed The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Procarbazine. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Procarbazine. Almotriptan The metabolism of Almotriptan can be decreased when combined with Procarbazine. Alogliptin Procarbazine may increase the hypoglycemic activities of Alogliptin. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Procarbazine. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Procarbazine. Alteplase The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Alteplase. Altretamine Altretamine may increase the orthostatic hypotensive activities of Procarbazine. Alverine The risk or severity of adverse effects can be increased when Procarbazine is combined with Alverine. Amantadine The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Procarbazine. Ambrisentan Procarbazine may increase the hypotensive activities of Ambrisentan. Amifostine Procarbazine may increase the orthostatic hypotensive activities of Amifostine. Amiloride Procarbazine may increase the orthostatic hypotensive activities of Amiloride. Amiodarone Procarbazine may increase the orthostatic hypotensive activities of Amiodarone. Amisulpride The risk or severity of adverse effects can be increased when Procarbazine is combined with Amisulpride. Amitriptyline Procarbazine may increase the serotonergic activities of Amitriptyline. Amitriptylinoxide Procarbazine may increase the serotonergic activities of Amitriptylinoxide. Amlodipine Procarbazine may increase the hypotensive activities of Amlodipine. Amobarbital The risk or severity of adverse effects can be increased when Procarbazine is combined with Amobarbital. Amoxapine Procarbazine may increase the serotonergic activities of Amoxapine. Amphetamine Procarbazine may increase the hypertensive activities of Amphetamine. Amphotericin B Procarbazine may increase the orthostatic hypotensive activities of Amphotericin B. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Procarbazine. Amyl Nitrite Procarbazine may increase the orthostatic hypotensive activities of Amyl Nitrite. Anagrelide The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Anagrelide. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Procarbazine. Ancrod The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ancrod. Anifrolumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Anifrolumab. Anisotropine methylbromide Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide. Anistreplase The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Anistreplase. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Procarbazine. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Procarbazine. Antilymphocyte The risk or severity of adverse effects can be increased when Procarbazine is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Antithrombin Alfa. Antithrombin III human The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Antithrombin III human. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Procarbazine. Apixaban The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Apixaban. Apomorphine Procarbazine may increase the orthostatic hypotensive activities of Apomorphine. Apraclonidine Procarbazine may increase the alpha-adrenergic activities of Apraclonidine. Apremilast The risk or severity of adverse effects can be increased when Procarbazine is combined with Apremilast. Apronalide The risk or severity of adverse effects can be increased when Procarbazine is combined with Apronalide. Arbutamine The risk or severity of adverse effects can be increased when Procarbazine is combined with Arbutamine. Ardeparin The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ardeparin. Arformoterol The risk or severity of adverse effects can be increased when Procarbazine is combined with Arformoterol. Argatroban The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Argatroban. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Procarbazine. Aripiprazole lauroxil The risk or severity of serotonin syndrome can be increased when Aripiprazole lauroxil is combined with Procarbazine. Arsenic trioxide The risk or severity of adverse effects can be increased when Procarbazine is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Articaine. Asenapine The risk or severity of adverse effects can be increased when Procarbazine is combined with Asenapine. AstraZeneca The therapeutic efficacy of the AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Procarbazine. Atenolol Procarbazine may increase the hypotensive activities of Atenolol. Atomoxetine The risk or severity of adverse effects can be increased when Procarbazine is combined with Atomoxetine. Atorvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Atorvastatin is combined with Procarbazine. Atracurium The risk or severity of adverse effects can be increased when Procarbazine is combined with Atracurium. Atracurium besylate The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Procarbazine. Atropine The risk or severity of hypertension can be increased when Procarbazine is combined with Atropine. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Procarbazine. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Procarbazine. Azelastine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Azilsartan medoxomil Procarbazine may increase the hypotensive activities of Azilsartan medoxomil. Bacillus calmette-guerin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Procarbazine. Bacillus calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Procarbazine. Bacillus calmette-guerin The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Procarbazine. Baclofen The risk or severity of hypotension can be increased when Baclofen is combined with Procarbazine. Baricitinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Procarbazine. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Procarbazine. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Procarbazine. Belatacept The risk or severity of adverse effects can be increased when Procarbazine is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Procarbazine is combined with Belinostat. Belladonna Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Belladonna. Belumosudil The risk or severity of adverse effects can be increased when Procarbazine is combined with Belumosudil. Bemiparin The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Bemiparin. Benazepril Procarbazine may increase the hypotensive activities of Benazepril. Bendamustine The risk or severity of adverse effects can be increased when Procarbazine is combined with Bendamustine. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Procarbazine. Betaxolol Procarbazine may increase the hypotensive activities of Betaxolol. Bethanidine Procarbazine may increase the hypotensive activities of Bethanidine. Betrixaban The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Betrixaban. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Procarbazine. Bezafibrate Procarbazine may increase the hepatotoxic activities of Bezafibrate. Bimekizumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Bimekizumab. Biperiden Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Biperiden. Bisoprolol Procarbazine may increase the hypotensive activities of Bisoprolol. Bivalirudin The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Bivalirudin. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Procarbazine. Blinatumomab The risk or severity of adverse effects can be increased when Procarbazine is combined with Blinatumomab. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Procarbazine. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Procarbazine. Bosentan Procarbazine may increase the hypotensive activities of Bosentan. Bosutinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Bosutinib. Botulinum toxin type A The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Procarbazine. Botulinum toxin type B The risk or severity of adverse effects can be increased when Botulinum toxin type B is combined with Procarbazine. Brentuximab vedotin The risk or severity of adverse effects can be increased when Procarbazine is combined with Brentuximab vedotin. Bretylium Procarbazine may increase the hypotensive activities of Bretylium. Brexanolone The risk or severity of adverse effects can be increased when Procarbazine is combined with Brexanolone. Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Procarbazine. Brimonidine The metabolism of Brimonidine can be decreased when combined with Procarbazine. Brivaracetam The risk or severity of adverse effects can be increased when Procarbazine is combined with Brivaracetam. Brodalumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Brodalumab. Bromazepam The risk or severity of adverse effects can be increased when Procarbazine is combined with Bromazepam. Bromocriptine Procarbazine may increase the hypertensive activities of Bromocriptine. Bromperidol The risk or severity of adverse effects can be increased when Procarbazine is combined with Bromperidol. Brompheniramine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine. Buclizine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Buclizine. Budesonide The risk or severity of adverse effects can be increased when Procarbazine is combined with Budesonide. Bumetanide Procarbazine may increase the orthostatic hypotensive activities of Bumetanide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Bupivacaine. Buprenorphine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Bupropion The risk or severity of adverse effects can be increased when Procarbazine is combined with Bupropion. Buspirone The risk or severity of hypertension can be increased when Procarbazine is combined with Buspirone. Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Procarbazine. Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Procarbazine. Butacaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Butacaine. Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Procarbazine. Butamben The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Butamben. Butaperazine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Butaperazine. Butobarbital The risk or severity of adverse effects can be increased when Procarbazine is combined with Butobarbital. Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Procarbazine. Butriptyline Procarbazine may increase the serotonergic activities of Butriptyline. Butylscopolamine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine. Cabazitaxel The risk or severity of adverse effects can be increased when Procarbazine is combined with Cabazitaxel. Cabergoline The metabolism of Cabergoline can be decreased when combined with Procarbazine. Canagliflozin Procarbazine may increase the orthostatic hypotensive activities of Canagliflozin. Canakinumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Canakinumab. Candesartan cilexetil Procarbazine may increase the hypotensive activities of Candesartan cilexetil. Cangrelor The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Cangrelor. Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Procarbazine. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Procarbazine. Caplacizumab The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Caplacizumab. Capsaicin The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Capsaicin. Captopril Procarbazine may increase the hypotensive activities of Captopril. Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Procarbazine. Carbetocin Procarbazine may increase the orthostatic hypotensive activities of Carbetocin. Carbimazole The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Procarbazine. Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Procarbazine. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Procarbazine. Carfilzomib The risk or severity of adverse effects can be increased when Procarbazine is combined with Carfilzomib. Cariprazine The metabolism of Cariprazine can be decreased when combined with Procarbazine. Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Procarbazine. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Procarbazine. Carvedilol Procarbazine may increase the hypotensive activities of Carvedilol. Celiprolol Procarbazine may increase the hypotensive activities of Celiprolol. Cerivastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Procarbazine. Certolizumab pegol The risk or severity of adverse effects can be increased when Procarbazine is combined with Certolizumab pegol. Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Procarbazine. Chloral hydrate The risk or severity of adverse effects can be increased when Procarbazine is combined with Chloral hydrate. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Procarbazine. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Procarbazine. Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Procarbazine. Chlormezanone The risk or severity of adverse effects can be increased when Procarbazine is combined with Chlormezanone. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Chloroprocaine. Chloroquine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Procarbazine. Chlorothiazide Procarbazine may increase the hypotensive activities of Chlorothiazide. Chlorpheniramine The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Procarbazine. Chlorpromazine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Chlorpromazine. Chlorpropamide Procarbazine may increase the hypoglycemic activities of Chlorpropamide. Chlorprothixene Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. Chlorthalidone Procarbazine may increase the hypotensive activities of Chlorthalidone. Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Procarbazine. Ciclesonide The risk or severity of adverse effects can be increased when Procarbazine is combined with Ciclesonide. Cilazapril Procarbazine may increase the hypotensive activities of Cilazapril. Cilostazol The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Cilostazol. Cimetidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Procarbazine. Dantrolene The risk or severity of adverse effects can be increased when Procarbazine is combined with Dantrolene. Dapagliflozin Procarbazine may increase the orthostatic hypotensive activities of Dapagliflozin. Daptomycin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Procarbazine. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Procarbazine. Daridorexant The risk or severity of CNS depression can be increased when Procarbazine is combined with Daridorexant. Darifenacin Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin. Dasatinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Dasatinib. Dasiglucagon Procarbazine may increase the hypotensive activities of Dasiglucagon. Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Procarbazine. Debrisoquine Procarbazine may increase the hypotensive activities of Debrisoquine. Decamethonium The risk or severity of adverse effects can be increased when Procarbazine is combined with Decamethonium. Decitabine The risk or severity of adverse effects can be increased when Procarbazine is combined with Decitabine. Defibrotide The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Defibrotide. Deflazacort The risk or severity of adverse effects can be increased when Procarbazine is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Procarbazine. Deserpidine Procarbazine may increase the hypotensive activities of Deserpidine. Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Procarbazine. Desipramine Procarbazine may increase the serotonergic activities of Desipramine. Desirudin The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Desirudin. Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Procarbazine. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Procarbazine. Desvenlafaxine Procarbazine may increase the serotonergic activities of Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Deucravacitinib. Deutetrabenazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Deutetrabenazine. Dexamethasone The risk or severity of adverse effects can be increased when Procarbazine is combined with Dexamethasone. Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Procarbazine. Dexfenfluramine The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Dexfenfluramine. Dexmedetomidine Procarbazine may increase the orthostatic hypotensive activities of Dexmedetomidine. Dexmethylphenidate Procarbazine may increase the hypertensive activities of Dexmethylphenidate. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Procarbazine. Dextran The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Dextran. Dextroamphetamine Procarbazine may increase the hypertensive activities of Dextroamphetamine. Dextromethorphan The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Dextromethorphan. Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Procarbazine. Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Procarbazine. Diamorphine The risk or severity of adverse effects can be increased when Diamorphine is combined with Procarbazine. Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Procarbazine. Diazoxide Procarbazine may increase the hypotensive activities of Diazoxide. Dibenzepin Procarbazine may increase the serotonergic activities of Dibenzepin Duloxetine The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Duloxetine. Dyclonine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Dyclonine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Procarbazine. Eculizumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Eculizumab. Edetic acid The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Edetic acid. Edoxaban The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Procarbazine. Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Procarbazine. Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Procarbazine. Eluxadoline The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Eluxadoline. Emapalumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Emapalumab. Empagliflozin Procarbazine may increase the orthostatic hypotensive activities of Empagliflozin. Enalapril Procarbazine may increase the hypotensive activities of Enalapril. Enalaprilat Procarbazine may increase the hypotensive activities of Enalaprilat. Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Procarbazine. Enoxaparin The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Enoxaparin. Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Procarbazine. Epinastine The risk or severity of adverse effects can be increased when Epinastine is combined with Procarbazine. Epinephrine Procarbazine may increase the hypertensive activities of Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Procarbazine. Eplerenone Procarbazine may increase the hypotensive activities of Eplerenone. Epoprostenol Procarbazine may increase the hypotensive activities of Epoprostenol. Eprosartan Procarbazine may increase the hypotensive activities of Eprosartan. Eptifibatide The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Eptifibatide. Ergoloid mesylate The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Procarbazine. Ergometrine Procarbazine may increase the hypertensive activities of Ergometrine. Ergotamine The metabolism of Ergotamine can be decreased when combined with Procarbazine. Eribulin The risk or severity of adverse effects can be increased when Procarbazine is combined with Eribulin. Ertugliflozin Procarbazine may increase the hypoglycemic activities of Ertugliflozin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Procarbazine. Escitalopram The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Escitalopram. Esketamine The risk or severity of adverse effects can be increased when Procarbazine is combined with Esketamine. Eslicarbazepine The risk or severity of adverse effects can be increased when Procarbazine is combined with Eslicarbazepine. Eslicarbazepine acetate The risk or severity of adverse effects can be increased when Procarbazine is combined with Eslicarbazepine acetate. Esmolol Procarbazine may increase the hypotensive activities of Esmolol. Estazolam The risk or severity of adverse effects can be increased when Procarbazine is combined with Estazolam. Estramustine The risk or severity of adverse effects can be increased when Procarbazine is combined with Estramustine. Eszopiclone The risk or severity of CNS depression can be increased when Procarbazine is combined with Eszopiclone. Etacrynic acid Procarbazine may increase the orthostatic hypotensive activities of Etacrynic acid. Etafedrine The risk or severity of adverse effects can be increased when Procarbazine is combined with Etafedrine. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Procarbazine. Ethanol The risk or severity of adverse effects can be increased when Procarbazine is combined with Ethanol. Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Procarbazine. Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Procarbazine. Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Procarbazine. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Etidocaine. Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Procarbazine. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Procarbazine. Everolimus The risk or severity of adverse effects can be increased when Procarbazine is combined with Everolimus. Exenatide Procarbazine may increase the hypoglycemic activities of Exenatide. Ezogabine The risk or severity of adverse effects can be increased when Procarbazine is combined with Ezogabine. Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Procarbazine. Felodipine Procarbazine may increase the hypotensive activities of Felodipine. Fenfluramine The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Fenfluramine. Fenofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fenofibrate is combined with Procarbazine. Fenofibric acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Fenofibric acid. Fenoldopam Procarbazine may increase the hypotensive activities of Fenoldopam. Fenoterol The risk or severity of adverse effects can be increased when Procarbazine is combined with Fenoterol. Fentanyl The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Fentanyl. Fesoterodine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine. Filgotinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Filgotinib. Fingolimod Procarbazine may increase the immunosuppressive activities of Fingolimod. Flavoxate Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate. Flibanserin The metabolism of Flibanserin can be decreased when combined with Procarbazine. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Procarbazine. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Procarbazine. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Procarbazine. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Procarbazine. Fluindione The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Fluindione. Flunarizine The risk or severity of adverse effects can be increased when Procarbazine is combined with Flunarizine. Ipratropium Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium. Irbesartan Procarbazine may increase the hypotensive activities of Irbesartan. Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Procarbazine. Isocarboxazid The risk or severity of adverse effects can be increased when Procarbazine is combined with Isocarboxazid. Isoetharine The risk or severity of adverse effects can be increased when Procarbazine is combined with Isoetharine. Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Procarbazine. Isometheptene Procarbazine may increase the sympathomimetic activities of Isometheptene. Isoniazid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Procarbazine. Isoprenaline The risk or severity of adverse effects can be increased when Procarbazine is combined with Isoprenaline. Isopropamide Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide. Isosorbide dinitrate Procarbazine may increase the orthostatic hypotensive activities of Isosorbide dinitrate. Isosorbide mononitrate Procarbazine may increase the orthostatic hypotensive activities of Isosorbide mononitrate. Isotretinoin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Procarbazine. Isoxsuprine Procarbazine may increase the orthostatic hypotensive activities of Isoxsuprine. Isradipine Procarbazine may increase the hypotensive activities of Isradipine. Ivermectin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Procarbazine. Ixabepilone The risk or severity of adverse effects can be increased when Procarbazine is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Ixekizumab. Janssen COVID-19 The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Procarbazine. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Procarbazine. Ketamine The risk or severity of adverse effects can be increased when Procarbazine is combined with Ketamine. Ketazolam The risk or severity of adverse effects can be increased when Procarbazine is combined with Ketazolam. Labetalol Procarbazine may increase the hypotensive activities of Labetalol. Lacidipine Procarbazine may increase the hypotensive activities of Lacidipine. Lacosamide The risk or severity of adverse effects can be increased when Procarbazine is combined with Lacosamide. Lamivudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Procarbazine. Lamotrigine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine. Lasmiditan The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Procarbazine. Leflunomide The risk or severity of adverse effects can be increased when Procarbazine is combined with Leflunomide. Lemborexant The risk or severity of adverse effects can be increased when Procarbazine is combined with Lemborexant. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Procarbazine. Lepirudin The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Lepirudin. Lercanidipine Procarbazine may increase the hypotensive activities of Lercanidipine. Letrozole The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Procarbazine. Leuprolide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Procarbazine. Levacetylmethadol The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Procarbazine. Levamlodipine Procarbazine may increase the hypotensive activities of Levamlodipine. Levetiracetam The risk or severity of adverse effects can be increased when Procarbazine is combined with Levetiracetam. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Levobupivacaine. Levocetirizine The risk or severity of adverse effects can be increased when Procarbazine is combined with Levocetirizine. Levodopa Procarbazine may increase the orthostatic hypotensive activities of Levodopa. Levomilnacipran Procarbazine may increase the serotonergic activities of Levomilnacipran. Levonordefrin Procarbazine may increase the hypertensive activities of Levonordefrin. Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Procarbazine. Levosalbutamol The risk or severity of adverse effects can be increased when Procarbazine is combined with Levosalbutamol. Levosimendan Procarbazine may increase the orthostatic hypotensive activities of Levosimendan. Lidocaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Lidocaine. Linagliptin Procarbazine may increase the hypoglycemic activities of Linagliptin. Linezolid The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Linezolid. Lipegfilgrastim Procarbazine may increase the myelosuppressive activities of Lipegfilgrastim. Liraglutide Procarbazine may increase the hypoglycemic activities of Liraglutide. Lisdexamfetamine Procarbazine may increase the hypertensive activities of Lisdexamfetamine. Lisinopril Procarbazine may increase the hypotensive activities of Lisinopril. Lisuride The metabolism of Lisuride can be decreased when combined with Procarbazine. Lithium carbonate The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Lithium carbonate. Lithium citrate The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Lithium citrate. Lithium hydroxide The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Lithium hydroxide. Lixisenatide Procarbazine may increase the hypoglycemic activities of Lixisenatide. Lofexidine The therapeutic efficacy of Procarbazine can be increased when used in combination with Lofexidine. Lomustine The risk or severity of adverse effects can be increased when Procarbazine is combined with Lomustine. Lopinavir The serum concentration of Procarbazine can be increased when it is combined with Lopinavir. Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Procarbazine. Lorcaserin The risk or severity of adverse effects can be increased when Procarbazine is combined with Lorcaserin. Lormetazepam The risk or severity of adverse effects can be increased when Procarbazine is combined with Lormetazepam. Lorpiprazole The risk or severity of adverse effects can be increased when Procarbazine is combined with Lorpiprazole. Losartan Procarbazine may increase the hypotensive activities of Losartan. Lovastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Procarbazine. Loxapine The risk or severity of adverse effects can be increased when Procarbazine is combined with Loxapine. Lumateperone The risk or severity of adverse effects can be increased when Procarbazine is combined with Lumateperone. Lurasidone The risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone. Macitentan Procarbazine may increase the hypotensive activities of Macitentan. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Procarbazine. Magnesium sulfate The therapeutic efficacy of Procarbazine can be increased when used in combination with Magnesium sulfate. Manidipine Procarbazine may increase the hypotensive activities of Manidipine. Mannitol Procarbazine may increase the orthostatic hypotensive activities of Mannitol. Maprotiline The risk or severity of adverse effects can be increased when Procarbazine is combined with Maprotiline. Mazindol The risk or severity of adverse effects can be increased when Mazindol is combined with Procarbazine. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Procarbazine. Mebeverine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine. Montelukast The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Procarbazine. Moricizine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Moricizine. Morphine Procarbazine may increase the analgesic activities of Morphine. Mosunetuzumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Mosunetuzumab. Moxonidine Procarbazine may increase the hypotensive activities of Moxonidine. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Procarbazine. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Procarbazine. Muzolimine Procarbazine may increase the hypotensive activities of Muzolimine. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Procarbazine. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Procarbazine. Niacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Procarbazine. Nialamide The risk or severity of adverse effects can be increased when Procarbazine is combined with Nialamide. Nicardipine Procarbazine may increase the hypotensive activities of Nicardipine. Nicorandil Procarbazine may increase the hypotensive activities of Nicorandil. Nifedipine Procarbazine may increase the orthostatic hypotensive activities of Nifedipine. Nilotinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Nilotinib. Nilvadipine Procarbazine may increase the hypotensive activities of Nilvadipine. Nimesulide The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Nimesulide. Nimodipine Procarbazine may increase the hypotensive activities of Nimodipine. Nisoldipine Procarbazine may increase the hypotensive activities of Nisoldipine. Nitrazepam The risk or severity of adverse effects can be increased when Procarbazine is combined with Nitrazepam. Nitrendipine Procarbazine may increase the hypotensive activities of Nitrendipine. Nitric Oxide Procarbazine may increase the orthostatic hypotensive activities of Nitric Oxide. Nitroglycerin Procarbazine may increase the hypotensive activities of Nitroglycerin. Nitroprusside Procarbazine may increase the hypotensive activities of Nitroprusside. Nitrous acid Procarbazine may increase the orthostatic hypotensive activities of Nitrous acid. Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Procarbazine. Nizatidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Procarbazine. Nomifensine The risk or severity of adverse effects can be increased when Procarbazine is combined with Nomifensine. Norepinephrine Procarbazine may increase the hypertensive activities of Norepinephrine. Norfloxacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Norfloxacin is combined with Procarbazine. Normethadone The risk or severity of adverse effects can be increased when Normethadone is combined with Procarbazine. Nortriptyline Procarbazine may increase the serotonergic activities of Nortriptyline. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Procarbazine. Obinutuzumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Obinutuzumab. Ocrelizumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Ocrelizumab. Ofatumumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Ofatumumab. Ofloxacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ofloxacin is combined with Procarbazine. Olanzapine Procarbazine may increase the orthostatic hypotensive activities of Olanzapine. Olaparib The risk or severity of adverse effects can be increased when Procarbazine is combined with Olaparib. Oliceridine The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Procarbazine is combined with Oliceridine. Olmesartan Procarbazine may increase the hypotensive activities of Olmesartan. Olodaterol The risk or severity of adverse effects can be increased when Procarbazine is combined with Olodaterol. Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Procarbazine. Opicapone Procarbazine may increase the orthostatic hypotensive activities of Opicapone. Opium The risk or severity of adverse effects can be increased when Opium is combined with Procarbazine. Orciprenaline The risk or severity of adverse effects can be increased when Procarbazine is combined with Orciprenaline. Orphenadrine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Procarbazine. Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Procarbazine. Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Procarbazine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Oxetacaine. Oxitriptan The risk or severity of adverse effects can be increased when Procarbazine is combined with Oxitriptan. Oxprenolol Procarbazine may increase the hypotensive activities of Oxprenolol. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Oxybuprocaine. Oxybutynin Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin. Oxycodone Procarbazine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone. Oxymetazoline The serum concentration of Oxymetazoline can be increased when it is combined with Procarbazine. Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Procarbazine. Oxyphencyclimine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine. Oxyphenonium Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium. Ozanimod The risk or severity of adverse effects can be increased when Procarbazine is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Procarbazine is combined with Paclitaxel. Palbociclib The risk or severity of adverse effects can be increased when Procarbazine is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Procarbazine. Paliperidone The risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone. Palonosetron The risk or severity of adverse effects can be increased when Palonosetron is combined with Procarbazine. Pamidronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Procarbazine. Pancuronium Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium. Panobinostat The risk or severity of adverse effects can be increased when Procarbazine is combined with Panobinostat. Papaverine Procarbazine may increase the orthostatic hypotensive activities of Papaverine. Paraldehyde Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Paramethadione The risk or severity of adverse effects can be increased when Paramethadione is combined with Procarbazine. Pargyline The risk or severity of adverse effects can be increased when Procarbazine is combined with Pargyline. Parnaparin The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Parnaparin. Paroxetine Procarbazine may increase the serotonergic activities of Paroxetine. Pazopanib The risk or severity of adverse effects can be increased when Procarbazine is combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Procarbazine. Pegcetacoplan The risk or severity of adverse effects can be increased when Procarbazine is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Procarbazine. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Procarbazine. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Procarbazine. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Procarbazine is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Procarbazine. Penbutolol Procarbazine may increase the hypotensive activities of Penbutolol. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Procarbazine. Pentamidine Procarbazine may increase the hypoglycemic activities of Pentamidine. Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Procarbazine. Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Procarbazine. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Procarbazine. Rivaroxaban The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Rivaroxaban. Rizatriptan The metabolism of Rizatriptan can be decreased when combined with Procarbazine. Rocuronium Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium. Roflumilast Roflumilast may increase the immunosuppressive activities of Procarbazine. Ropeginterferon alfa-2b The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Procarbazine. Ropinirole Procarbazine may increase the sedative activities of Ropinirole. Ropivacaine The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Ropivacaine. Rosiglitazone Procarbazine may increase the hypoglycemic activities of Rosiglitazone. Rosuvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Rosuvastatin is combined with Procarbazine. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Procarbazine. Rotigotine Procarbazine may increase the sedative activities of Rotigotine. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Procarbazine. Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Procarbazine. Ruxolitinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Ruxolitinib. Sacubitril Procarbazine may increase the orthostatic hypotensive activities of Sacubitril. Safinamide The risk or severity of adverse effects can be increased when Procarbazine is combined with Safinamide. Salbutamol The risk or severity of adverse effects can be increased when Procarbazine is combined with Salbutamol. Salmeterol The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Procarbazine. Saquinavir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Saquinavir. Sarilumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Satralizumab. Saxagliptin Procarbazine may increase the hypoglycemic activities of Saxagliptin. Scopolamine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine. Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Procarbazine. Secukinumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Secukinumab. Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Procarbazine. Selexipag Procarbazine may increase the hypotensive activities of Selexipag. Semaglutide Procarbazine may increase the hypoglycemic activities of Semaglutide. Serdexmethylphenidate The risk or severity of adverse effects can be increased when Procarbazine is combined with Serdexmethylphenidate. Sertindole The risk or severity of adverse effects can be increased when Procarbazine is combined with Sertindole. Sertraline The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Procarbazine. Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Procarbazine. Sibutramine Procarbazine may increase the serotonergic activities of Sibutramine. Sildenafil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Procarbazine. Siltuximab The risk or severity of adverse effects can be increased when Procarbazine is combined with Siltuximab. Simvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Procarbazine. Siponimod The risk or severity of adverse effects can be increased when Procarbazine is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Procarbazine. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Procarbazine. Sitagliptin Procarbazine may increase the hypoglycemic activities of Sitagliptin. Sitaxentan Procarbazine may increase the hypotensive activities of Sitaxentan. Smallpox (Vaccinia) The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Procarbazine. Sodium citrate The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Sodium citrate. Sodium oxybate Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. Solifenacin Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin. Solriamfetol The risk or severity of adverse effects can be increased when Procarbazine is combined with Solriamfetol. Somatotropin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Procarbazine. Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Procarbazine. Sotagliflozin Procarbazine may increase the hypoglycemic activities of Sotagliflozin. Sotalol Procarbazine may increase the orthostatic hypotensive activities of Sotalol. Spesolimab The risk or severity of adverse effects can be increased when Procarbazine is combined with Spesolimab. Spirapril Procarbazine may increase the hypotensive activities of Spirapril. Spironolactone Procarbazine may increase the orthostatic hypotensive activities of Spironolactone. St. John's Wort The risk or severity of adverse effects can be increased when Procarbazine is combined with St. John's Wort. Stavudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Procarbazine. Stiripentol The risk or severity of adverse effects can be increased when Procarbazine is combined with Stiripentol. Streptokinase Procarbazine may increase the orthostatic hypotensive activities of Streptokinase. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Procarbazine. Succinylcholine The risk or severity of adverse effects can be increased when Succinylcholine is combined with Procarbazine. Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Procarbazine. Sulfadiazine Procarbazine may increase the hypoglycemic activities of Sulfadiazine. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Procarbazine. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Procarbazine. Sulfinpyrazone The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Sulfinpyrazone. Sulfisoxazole Procarbazine may increase the hypoglycemic activities of Sulfisoxazole. Sulodexide The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Sulodexide. Sulpiride The risk or severity of adverse effects can be increased when Procarbazine is combined with Sulpiride. Sulthiame The risk or severity of adverse effects can be increased when Procarbazine is combined with Sulthiame. Sultopride The risk or severity of adverse effects can be increased when Procarbazine is combined with Sultopride. Sumatriptan The metabolism of Sumatriptan can be decreased when combined with Procarbazine. Sunitinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Sunitinib. Suvorexant Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Thiopental Procarbazine may increase the orthostatic hypotensive activities of Thiopental. Thioridazine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Thioridazine. Thiotepa The risk or severity of adverse effects can be increased when Procarbazine is combined with Thiotepa. Thiothixene The risk or severity of adverse effects can be increased when Procarbazine is combined with Thiothixene. Thonzylamine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine. Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Procarbazine. Ticagrelor The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ticagrelor. Tick-borne encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Procarbazine. Ticlopidine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Ticlopidine. Timolol Procarbazine may increase the hypotensive activities of Timolol. Tinzaparin The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Tinzaparin. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Procarbazine. Tiotropium Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Tiotropium. Tirofiban The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Tirofiban. Tirzepatide Procarbazine may increase the hypoglycemic activities of Tirzepatide. Tixocortol The risk or severity of adverse effects can be increased when Procarbazine is combined with Tixocortol. Tizanidine Procarbazine may increase the orthostatic hypotensive activities of Tizanidine. Tocilizumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Tocilizumab. Tofacitinib Procarbazine may increase the immunosuppressive activities of Tofacitinib. Tolazamide Procarbazine may increase the hypoglycemic activities of Tolazamide. Tolazoline Procarbazine may increase the hypotensive activities of Tolazoline. Tolbutamide Procarbazine may increase the hypoglycemic activities of Tolbutamide. Tolcapone Procarbazine may increase the orthostatic hypotensive activities of Tolcapone. Tolterodine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine. Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Procarbazine. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Procarbazine. Torasemide Procarbazine may increase the hypotensive activities of Torasemide. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Procarbazine. Trabectedin The risk or severity of adverse effects can be increased when Procarbazine is combined with Trabectedin. Tramadol The risk or severity of serotonin syndrome and seizure can be increased when Procarbazine is combined with Tramadol. Trandolapril Procarbazine may increase the hypotensive activities of Trandolapril. Tranylcypromine The risk or severity of adverse effects can be increased when Procarbazine is combined with Tranylcypromine. Trastuzumab Trastuzumab may increase the neutropenic activities of Procarbazine. Trastuzumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Trastuzumab emtansine. Trazodone Procarbazine may increase the serotonergic activities of Trazodone. Treprostinil Procarbazine may increase the hypotensive activities of Treprostinil. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Procarbazine. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Procarbazine. Triamterene Procarbazine may increase the orthostatic hypotensive activities of Triamterene. Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Procarbazine. Trichlormethiazide Procarbazine may increase the hypotensive activities of Trichlormethiazide. Trichloroethylene The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Procarbazine. Triclofos The risk or severity of adverse effects can be increased when Procarbazine is combined with Triclofos. Trifluoperazine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Trifluoperazine. Triflupromazine The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Triflupromazine. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Procarbazine. Triflusal The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Triflusal. Trihexyphenidyl Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Procarbazine. Trimebutine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine. Trimethadione The risk or severity of adverse effects can be increased when Trimethadione is combined with Procarbazine. Trimethaphan Procarbazine may increase the hypotensive activities of Trimethaphan. Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Procarbazine. Trimethoprim The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Procarbazine. Trimipramine Procarbazine may increase the serotonergic activities of Trimipramine. Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Procarbazine. Troglitazone Procarbazine may increase the hypoglycemic activities of Troglitazone. Tropisetron The risk or severity of adverse effects can be increased when Procarbazine is combined with Tropisetron. Trospium Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Trospium. Tryptophan The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Procarbazine. Tubocurarine The risk or severity of adverse effects can be increased when Procarbazine is combined with Tubocurarine. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Procarbazine. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Procarbazine. Typhoid Vi polysaccharide The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Procarbazine. Ubidecarenone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Ubidecarenone. Umeclidinium Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Umeclidinium. Upadacitinib The risk or severity of adverse effects can be increased when Procarbazine is combined with Upadacitinib. Urethane The risk or severity of adverse effects can be increased when Procarbazine is combined with Urethane. Urokinase The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Urokinase. Valproate bismuth The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Valproate bismuth. Valproic acid The risk or severity of adverse effects can be increased when Valproic acid is combined with Procarbazine. Valsartan Procarbazine may increase the hypotensive activities of Valsartan. Varicella zoster vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Procarbazine. Varicella zoster vaccine The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Procarbazine. Vecuronium The risk or severity of adverse effects can be increased when Procarbazine is combined with Vecuronium. Vedolizumab The risk or severity of adverse effects can be increased when Procarbazine is combined with Vedolizumab. Venlafaxine The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Venlafaxine. Verapamil Procarbazine may increase the orthostatic hypotensive activities of Verapamil. Vericiguat Procarbazine may increase the orthostatic hypotensive activities of Vericiguat. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Procarbazine. Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Procarbazine. Vilanterol The risk or severity of adverse effects can be increased when Procarbazine is combined with Vilanterol. Vilazodone The metabolism of Vilazodone can be decreased when combined with Procarbazine. Vildagliptin Procarbazine may increase the hypoglycemic activities of Vildagliptin. Viloxazine The risk or severity of hypertension can be increased when Viloxazine is combined with Procarbazine. Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Procarbazine. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Procarbazine. Pregnancy and Lactation FDA Pregnancy Category D Pregnancy There is a possibility of birth defects if either the father or mother is taking procarbazine at the time of conception, or if it is taken during pregnancy. This medication should not be used during pregnancy unless the benefits outweigh the risks. Use effective birth control while you are being treated with this medication. If you become pregnant while taking this medication, contact your doctor immediately. Breast-feeding It is not known if procarbazine passes into breast milk. If you are a breast-feeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breast-feeding. How should this medicine be used?

Procarbazine comes as a capsule to take by mouth. It is usually taken one or more times a day. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have. Take procarbazine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take procarbazine exactly…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    Cholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    Imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    A thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    Propylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    Methimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    Mirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)